Petros Pharmaceuticals completes Human Factors Study for STENDRA

Petros Pharmaceuticals announces the completion of a Human Factors Study, whose objective was to assess the technology component developed to facilitate patient’s access to its erectile dysfunction drug, STENDRA, associated with the Company’s intended FDA application for prescription to OTC switch. The objective of the study was to determine the strengths and weaknesses of the interface of a developmental technology tool, as well as potential use errors in critical tasks, such as navigating and reporting medical history, entering birth date and other key call to action prompts. These tasks, if performed incorrectly – or not performed at all – have the potential to contribute to inappropriate use by the patient or user. The results of the study showed that most participants were able to navigate the tool correctly. Data from the study provided an opportunity for the Company to further optimize this technology, including reformatting of text to improve interaction, which Petros intends to implement in future studies, including additional Human Factor Studies and Self Selection studies. These components are all integral to FDA guidelines for technology-driven OTC access to medications.